89Zr-DFO-girentuximab PET/CT imaging can accurately detect clear cell renal cell carcinoma primary and secondary lesions in patients with renal masses at conventional imaging, results from ZIRCON phase 3 study Meeting Abstract

  


Authors: Calais, J.; Shuch, B.; Pantuck, A.; Bernhard, J. C.; Morris, M.; Master, V.; Scott, A.; van Praet, C.; Bailly, C.; Aksoy, T.; Merkx, R.; Schuster, D.; Lee, S. T.; Pandit-Taskar, N.; Fan, A.; Tauchmanova, L.; Allman, P.; Schmidt, K.; Vadali, K.; Hayward, C.; Mulders, P.
Abstract Title: 89Zr-DFO-girentuximab PET/CT imaging can accurately detect clear cell renal cell carcinoma primary and secondary lesions in patients with renal masses at conventional imaging, results from ZIRCON phase 3 study
Meeting Title: 2023 SNMMI Annual Meeting
Journal Title: Journal of Nuclear Medicine
Volume: 64
Issue: Suppl. 1
Meeting Dates: 2023 Jun 24-27
Meeting Location: Chicago, IL
ISSN: 0161-5505
Publisher: Society of Nuclear Medicine  
Date Published: 2023-06-01
Language: English
ACCESSION: WOS:001109210202125
PROVIDER: wos
Notes: Meeting Abstract: P1113 -- Source: Wos